Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Impact of next generation sequencing defined HIV pre-treatment drug resistance on virological outcomes in the ANRS 12249 treatment as prevention trial.

Derache A, Iwuji CC, Baisley K, Danaviah S, Marcelin AG, Calvez V, de Oliveira T, Dabis F, Porter K, Pillay D.

Clin Infect Dis. 2018 Oct 15. doi: 10.1093/cid/ciy881. [Epub ahead of print]

PMID:
30321314
2.

HIV Drug Resistance in Antiretroviral Treatment-Naïve Individuals in the Largest Public Hospital in Nicaragua, 2011-2015.

Avila-Ríos S, García-Morales C, Matías-Florentino M, Tapia-Trejo D, Hernández-Álvarez BF, Moreira-López SE, Quant-Durán CJ, Porras-Cortés G, Reyes-Terán G.

PLoS One. 2016 Oct 13;11(10):e0164156. doi: 10.1371/journal.pone.0164156. eCollection 2016.

3.

Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.

Ávila-Ríos S, García-Morales C, Matías-Florentino M, Romero-Mora KA, Tapia-Trejo D, Quiroz-Morales VS, Reyes-Gopar H, Ji H, Sandstrom P, Casillas-Rodríguez J, Sierra-Madero J, León-Juárez EA, Valenzuela-Lara M, Magis-Rodríguez C, Uribe-Zuñiga P, Reyes-Terán G; HIVDR MexNet Group.

Lancet HIV. 2016 Dec;3(12):e579-e591. doi: 10.1016/S2352-3018(16)30119-9. Epub 2016 Sep 14.

PMID:
27658867
4.

Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.

HIV Med. 2013 Oct;14(9):571-7. doi: 10.1111/hiv.12044. Epub 2013 May 13.

5.

Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.

Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, Kanki P, Hoffmann CJ, Lockman S, Pillay D, de Oliveira T, Clumeck N, Hunt G, Kerschberger B, Shafer RW, Yang C, Raizes E, Kantor R, Gupta RK.

Lancet Infect Dis. 2017 Mar;17(3):296-304. doi: 10.1016/S1473-3099(16)30469-8. Epub 2016 Dec 1.

6.
7.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
8.

The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.

Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):140-6. doi: 10.1097/QAI.0b013e3181a56e81.

PMID:
19352201
9.

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.

Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, Incardona F, Zazzi M, Sönnerborg A.

PLoS One. 2017 Jun 5;12(6):e0178942. doi: 10.1371/journal.pone.0178942. eCollection 2017.

10.

Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.

Todesco E, Rodriguez C, Morand-Joubert L, Mercier-Darty M, Desire N, Wirden M, Girard PM, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2015 May;70(5):1503-6. doi: 10.1093/jac/dku557. Epub 2015 Jan 21.

PMID:
25614045
11.

The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.

Shearer K, Fox MP, Maskew M, Berhanu R, Long L, Sanne I.

PLoS One. 2013 Aug 7;8(8):e71719. doi: 10.1371/journal.pone.0071719. Print 2013.

12.

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group.

J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24.

13.

Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.

Gallien S, Charreau I, Nere ML, Mahjoub N, Simon F, de Castro N, Aboulker JP, Molina JM, Delaugerre C.

J Antimicrob Chemother. 2015 Feb;70(2):562-5. doi: 10.1093/jac/dku395. Epub 2014 Oct 25.

PMID:
25344807
14.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group.

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

15.

Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.

Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, Chapplain JM, Baysah M, Tattevin P, Yazdanpanah Y, Descamps D.

J Antimicrob Chemother. 2015;70(6):1881-4. doi: 10.1093/jac/dkv030. Epub 2015 Feb 18.

PMID:
25698771
16.

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.

Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.

HIV Clin Trials. 2015 Jan-Feb;16(1):30-8. doi: 10.1179/1528433614Z.0000000009. Epub 2015 Jan 21.

PMID:
25777187
17.

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.

Szubert AJ, Prendergast AJ, Spyer MJ, Musiime V, Musoke P, Bwakura-Dangarembizi M, Nahirya-Ntege P, Thomason MJ, Ndashimye E, Nkanya I, Senfuma O, Mudenge B, Klein N, Gibb DM, Walker AS; ARROW Trial Team.

PLoS Med. 2017 Nov 14;14(11):e1002432. doi: 10.1371/journal.pmed.1002432. eCollection 2017 Nov.

18.

Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?

Mzingwane ML, Tiemessen CT, Richter KL, Mayaphi SH, Hunt G, Bowyer SM.

Virol J. 2016 Oct 12;13(1):170.

19.

Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.

Rokx C, Fibriani A, van de Vijver DA, Verbon A, Schutten M, Gras L, Rijnders BJ; AIDS Therapy Evaluation in the Netherlands National Observational Cohort.

Clin Infect Dis. 2015 Jan 1;60(1):143-53. doi: 10.1093/cid/ciu763. Epub 2014 Oct 1.

PMID:
25273080
20.

HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.

Samuel R, Julian MN, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A, Gordon M.

J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):384-389.

Supplemental Content

Support Center